Skip to content
The Policy VaultThe Policy Vault

Brand Forteo — Blue Cross Blue Shield of Kansas

Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy

Preferred products

  • teriparatide (generic equivalent of Forteo)
  • Tymlos

Initial criteria

  • For BCBS KS, the preferred agents are teriparatide (generic equivalent of Forteo) and Tymlos. Requests for Brand Forteo, Teriparatide (branded generic), or Bonsity require prior authorization.
  • Use should be limited to the FDA approved indications for osteoporosis with high risk for fracture as defined by a history of osteoporotic fracture, multiple risk factors for fracture, or failure/intolerance to other osteoporosis therapy.
  • Use for more than 2 years in a patient's lifetime should only be considered if the patient remains at or has returned to having a high risk of fracture.

Reauthorization criteria

  • Reauthorization may be considered if the patient remains at or has returned to having a high risk of fracture.